Levalbuterol hydrochloride

D. Slattery, S. W. Wong, Andrew Colin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Racemic albuterol, a commonly used bronchodilator, is an exact 50:50 mixture of two enantiomers, R- and S-albuterol. Concern regarding increased mortality associated with the use of this beta-2 (β2) agonist triggered the study of both of these enantiomers separately. In vitro studies suggest that the two enantiomers have different binding affinities for β-adrenoreceptors, may exert opposing effects on inflammation, demonstrate different effects on mucocilary transport, and display differing pharmacokinetics. Clinical studies comparing both enantiomers are few, of short duration, and often in small patient populations, and their results vary. R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties. S-albuterol has markedly less affinity for the β-adrenoreceptor. It was found to cause bronchoconstriction in animal models, but neither bronchoconstrictive nor proinflammatory effects have been conclusively demonstrated in human studies. The data available at present, while suggestive, are insufficient to conclusively recommend R-albuterol over the racemate. Further basic research and investigations in humans comparing both enantiomers at increasing doses over longer time periods are required to clarify the precise roles of R- and S-albuterol.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalPediatric Pulmonology
Volume33
Issue number2
DOIs
StatePublished - Feb 14 2002
Externally publishedYes

Fingerprint

Levalbuterol
Albuterol
Bronchoconstriction
Bronchodilator Agents
Anti-Inflammatory Agents
Animal Models
Pharmacokinetics
Inflammation
Mortality

Keywords

  • Albuterol
  • Asthma
  • Beta-agonists
  • Enantiomer
  • Levalbuterol
  • Pharmacology
  • Racemate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Slattery, D., Wong, S. W., & Colin, A. (2002). Levalbuterol hydrochloride. Pediatric Pulmonology, 33(2), 151-157. https://doi.org/10.1002/ppul.10027

Levalbuterol hydrochloride. / Slattery, D.; Wong, S. W.; Colin, Andrew.

In: Pediatric Pulmonology, Vol. 33, No. 2, 14.02.2002, p. 151-157.

Research output: Contribution to journalArticle

Slattery, D, Wong, SW & Colin, A 2002, 'Levalbuterol hydrochloride', Pediatric Pulmonology, vol. 33, no. 2, pp. 151-157. https://doi.org/10.1002/ppul.10027
Slattery D, Wong SW, Colin A. Levalbuterol hydrochloride. Pediatric Pulmonology. 2002 Feb 14;33(2):151-157. https://doi.org/10.1002/ppul.10027
Slattery, D. ; Wong, S. W. ; Colin, Andrew. / Levalbuterol hydrochloride. In: Pediatric Pulmonology. 2002 ; Vol. 33, No. 2. pp. 151-157.
@article{bdbd5759decc4c97818ebdc0c97e50c3,
title = "Levalbuterol hydrochloride",
abstract = "Racemic albuterol, a commonly used bronchodilator, is an exact 50:50 mixture of two enantiomers, R- and S-albuterol. Concern regarding increased mortality associated with the use of this beta-2 (β2) agonist triggered the study of both of these enantiomers separately. In vitro studies suggest that the two enantiomers have different binding affinities for β-adrenoreceptors, may exert opposing effects on inflammation, demonstrate different effects on mucocilary transport, and display differing pharmacokinetics. Clinical studies comparing both enantiomers are few, of short duration, and often in small patient populations, and their results vary. R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties. S-albuterol has markedly less affinity for the β-adrenoreceptor. It was found to cause bronchoconstriction in animal models, but neither bronchoconstrictive nor proinflammatory effects have been conclusively demonstrated in human studies. The data available at present, while suggestive, are insufficient to conclusively recommend R-albuterol over the racemate. Further basic research and investigations in humans comparing both enantiomers at increasing doses over longer time periods are required to clarify the precise roles of R- and S-albuterol.",
keywords = "Albuterol, Asthma, Beta-agonists, Enantiomer, Levalbuterol, Pharmacology, Racemate",
author = "D. Slattery and Wong, {S. W.} and Andrew Colin",
year = "2002",
month = "2",
day = "14",
doi = "10.1002/ppul.10027",
language = "English",
volume = "33",
pages = "151--157",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Levalbuterol hydrochloride

AU - Slattery, D.

AU - Wong, S. W.

AU - Colin, Andrew

PY - 2002/2/14

Y1 - 2002/2/14

N2 - Racemic albuterol, a commonly used bronchodilator, is an exact 50:50 mixture of two enantiomers, R- and S-albuterol. Concern regarding increased mortality associated with the use of this beta-2 (β2) agonist triggered the study of both of these enantiomers separately. In vitro studies suggest that the two enantiomers have different binding affinities for β-adrenoreceptors, may exert opposing effects on inflammation, demonstrate different effects on mucocilary transport, and display differing pharmacokinetics. Clinical studies comparing both enantiomers are few, of short duration, and often in small patient populations, and their results vary. R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties. S-albuterol has markedly less affinity for the β-adrenoreceptor. It was found to cause bronchoconstriction in animal models, but neither bronchoconstrictive nor proinflammatory effects have been conclusively demonstrated in human studies. The data available at present, while suggestive, are insufficient to conclusively recommend R-albuterol over the racemate. Further basic research and investigations in humans comparing both enantiomers at increasing doses over longer time periods are required to clarify the precise roles of R- and S-albuterol.

AB - Racemic albuterol, a commonly used bronchodilator, is an exact 50:50 mixture of two enantiomers, R- and S-albuterol. Concern regarding increased mortality associated with the use of this beta-2 (β2) agonist triggered the study of both of these enantiomers separately. In vitro studies suggest that the two enantiomers have different binding affinities for β-adrenoreceptors, may exert opposing effects on inflammation, demonstrate different effects on mucocilary transport, and display differing pharmacokinetics. Clinical studies comparing both enantiomers are few, of short duration, and often in small patient populations, and their results vary. R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties. S-albuterol has markedly less affinity for the β-adrenoreceptor. It was found to cause bronchoconstriction in animal models, but neither bronchoconstrictive nor proinflammatory effects have been conclusively demonstrated in human studies. The data available at present, while suggestive, are insufficient to conclusively recommend R-albuterol over the racemate. Further basic research and investigations in humans comparing both enantiomers at increasing doses over longer time periods are required to clarify the precise roles of R- and S-albuterol.

KW - Albuterol

KW - Asthma

KW - Beta-agonists

KW - Enantiomer

KW - Levalbuterol

KW - Pharmacology

KW - Racemate

UR - http://www.scopus.com/inward/record.url?scp=0036161471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036161471&partnerID=8YFLogxK

U2 - 10.1002/ppul.10027

DO - 10.1002/ppul.10027

M3 - Article

VL - 33

SP - 151

EP - 157

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 2

ER -